Alpha-cyano-4-hydroxycinnamic acid alleviates renal fibrosis and inflammation in chronic kidney disease
نویسندگان
چکیده
Renal fibrosis is a crucial pathological phenomenon of chronic kidney disease (CKD) that contributes to the progressive loss renal function. Monocarboxylate transporter 1 (MCT1) plays an important role in clear cell carcinoma; however, MCT1 inhibitor alpha-cyano-4-hydroxycinnamic acid (α-CHCA) remains unclear. In this study, we evaluated α-CHCA, inhibitor, treating associated with CKD. We used α-CHCA CKD mouse model unilateral ureteral obstruction (UUO), and proximal tubular epithelial cells (mPTCs) stimulated by transforming growth factor-β1 (TGF-β1). vivo, administration improved tubulointerstitial fibrosis, which was consistent reduced expression collagen I/III, fibronectin (FN1), α-smooth muscle actin (α-SMA) kidneys UUO mice. Similarly, overexpression inflammatory factors decreased response treatment. vitro, pretreatment inhibited induction FN1, α-SMA production mPTCs treated TGF-β1. Collectively, these findings indicate may play therapeutic inhibiting deposition subsequent inflammation.Highlights Chronic mice have increased expression.α-CHCA, alleviates mice.α-CHCA improves inflammation inhibits TGF-β1-induced extracellular matrix secretion cells.
منابع مشابه
Suramin inhibits renal fibrosis in chronic kidney disease.
The activation of cytokine and growth factor receptors associates with the development and progression of renal fibrosis. Suramin is a compound that inhibits the interaction of several cytokines and growth factors with their receptors, but whether suramin inhibits the progression of renal fibrosis is unknown. Here, treatment of cultured renal interstitial fibroblasts with suramin inhibited thei...
متن کاملInflammation markers, chronic kidney disease, and renal replacement therapy.
Chronic kidney disease (CKD) is associated with a proinflammatory state and an excess of cardiovascular risk. In this work, we describe changes in inflammatory markers-C-reactive protein (CRP), pentraxin 3 (PTX3), serum component of amyloid A (SAA), and procalcitonin (PCT)--in CKD patients compared with a control group of subjects with a normal estimated glomerular filtration rate (eGFR). Blood...
متن کاملBioactivity Focus of α-Cyano-4-hydroxycinnamic acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors.
Bioactivity focus on α-cyano-4-hydroxycinnamic acid (CHCA) scaffold results in a small library of novel multifunctional aldose reductase (ALR2) inhibitors. All the entities displayed good to excellent inhibition with IC50 72-405 nM. (R,E)-N-(3-(2-acetamido-3-(benzyloxy)propanamido)propyl)-2-cyano-3-(4-hydroxy phenyl)acrylamide (5f) was confirmed as the most active inhibitor (IC50 72.7 ± 1.6 nM)...
متن کاملEndocrine disorders in chronic kidney disease
Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: All life
سال: 2023
ISSN: ['2689-5293', '2689-5307']
DOI: https://doi.org/10.1080/26895293.2023.2236310